FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
• Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with …
finanzen.ch flipped this story into finanzen.ch•22d
Related storyboards
More stories from Cancer
- On SIflipped into Ducks Digest
Oregon Ducks' Dan Lanning: 'Tough' Dillon Gabriel Injury Update After Michigan State Win
The Oregon Ducks remain undefeated with 31-10 victory over Michigan State. After the game, Oregon head coach Dan Lanning assessed quarterback Dillon …
Expert Doctors: This Hygiene Misstep Could Increase Your Risk of Head and Neck Cancer by 50%
Cancer researchers analyzed records from 160,000 patients to find that germs may influence the potential for a relatively common cancer type. Now …
Join the flipboard community
Discover, collect, and share stories for all your interests
Sign upMore stories from Finance
- Kevin Beachusflipped into Tesla And SpaceX
An $803-billion company most people have never heard of just knocked Tesla out of the Magnificent 7
With hardly anyone noticing, a tech titan you’ve probably never heard of has booted Tesla out of the heavily-hyped Magnificent Seven. Can it stay …
'What idiots we are': Truth Social users lose hundreds of thousands of dollars to scammers
A new report has published detailed complaints from users of former President Donald Trump's Truth Social app describing how they were fleeced by the …
- Haaretzflipped into Israel and Middle East News
Israel Considers Option of Exiling Sinwar, Hamas Leaders to Sudan as Part of Hostage Deal
Israeli officials are examining the possibility of exiling to Sudan Hamas leader Yahya Sinwar and other senior officials in the organization who …